menu
    • menu
    [{"orgOrder":0,"company":"Menlo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Minocycline Hydrochloride","moa":"","graph1":"Dermatology","graph2":"Approved","graph3":"Menlo Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Foam","sponsorNew":"Menlo Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Menlo Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Minocycline Hydrochloride","moa":"","graph1":"Dermatology","graph2":"Approved","graph3":"VYNE Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical","sponsorNew":"VYNE Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"VYNE Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Tarsier Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"ISRAEL","productType":"Undisclosed","year":"2020","type":"Not Applicable","leadProduct":"TRS01","moa":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Tarsier Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Eye Drop","sponsorNew":"Tarsier Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Tarsier Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Perrigo Company plc","sponsor":"Altaris Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Small molecule","year":"2021","type":"Divestment","leadProduct":"Adapalene","moa":"RAR","graph1":"Dermatology","graph2":"Approved","graph3":"Perrigo Company plc","amount2":1.55,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":1.55,"dosageForm":"Topical Cream","sponsorNew":"Perrigo Company plc \/ Altaris Capital Partners","highestDevelopmentStatusID":"12","companyTruncated":"Perrigo Company plc \/ Altaris Capital Partners"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Adapalene","moa":"RAR","graph1":"Dermatology","graph2":"Approved","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zydus Lifesciences \/ Not Applicable"},{"orgOrder":0,"company":"Ortho Dermatologics","sponsor":"Bausch Health","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Clindamycin Phosphate","moa":"50s ribosomal protein L1 inhibitor","graph1":"Dermatology","graph2":"Phase III","graph3":"Ortho Dermatologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Ortho Dermatologics \/ Bausch Health","highestDevelopmentStatusID":"10","companyTruncated":"Ortho Dermatologics \/ Bausch Health"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Adapalene","moa":"RAR-beta","graph1":"Dermatology","graph2":"Approved","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zydus Lifesciences \/ Not Applicable"},{"orgOrder":0,"company":"Ortho Dermatologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Clindamycin Hydrochloride","moa":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Ortho Dermatologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Ortho Dermatologics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ortho Dermatologics \/ Not Applicable"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Clindamycin Phosphate","moa":"","graph1":"Dermatology","graph2":"Approved","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Bausch Health \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bausch Health \/ Not Applicable"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Clindamycin Phosphate","moa":"","graph1":"Dermatology","graph2":"Approved","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Bausch Health \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bausch Health \/ Not Applicable"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Clindamycin Phosphate","moa":"","graph1":"Dermatology","graph2":"Approved","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"","sponsorNew":"Bausch Health \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bausch Health \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Adapalene

    Menu

    Adapalene

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
    filter

    Year

    filter

    DEALS // DEV.

    filter

    Country

    filter
    Sponsor
    filter

    Therapeutic Area

    filter

    Study Phase

    filter

    Deal Type

    filter

    Product Type

    filter

    Dosage Form

    filter

    Lead Product

    filter

    Target

    refresh Filters
    refresh Reset Filter
    refresh Reset Filter
    price-trend All Developments

    Therapeutic Area by Lead Product

    ForexGraph

    Study Phase by Lead Product

    ForexGraph

    Company by Lead Product

    ForexGraph

    Top Deals by Deal Size (USD bn)

    ForexGraph

    01

    Bausch Health

    Canada arrow
    Conjugates Summit
    Not Confirmed

    Bausch Health

    Canada arrow
    Conjugates Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Clindamycin Phosphate,Adapalene,Benzoyl Peroxide

    Therapeutic Area : Dermatology

    Study Phase : Approved

    Sponsor : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Health Canada Approves CABTREO™ for Acne Vulgaris in Patients 12 and Older

    Details : CABTREO (clindamycin phosphate, adapalene and benzoyl peroxide) topical gel is a prescription medicine indicated for acne vulgaris in patients 12 years of age and older.

    Product Name : Cabtreo

    Product Type : Small molecule

    Upfront Cash : Not Applicable

    September 11, 2024

    Lead Product(s) : Clindamycin Phosphate,Adapalene,Benzoyl Peroxide

    Therapeutic Area : Dermatology

    Highest Development Status : Approved

    Sponsor : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    02

    Bausch Health

    Canada arrow
    Conjugates Summit
    Not Confirmed

    Bausch Health

    Canada arrow
    Conjugates Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Clindamycin Phosphate,Adapalene,Benzoyl Peroxide

    Therapeutic Area : Dermatology

    Study Phase : Approved

    Sponsor : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    CABTREO™ Topical Gel for Acne Now Available in the U.S.

    Details : CABTREO (clindamycin phosphate, adapalene, benzoyl peroxide) topical gel is a prescription medicine which is now available in US for the topical treatment of acne vulgaris in age 12 years and older.

    Product Name : Cabtreo

    Product Type : Small molecule

    Upfront Cash : Not Applicable

    January 30, 2024

    Lead Product(s) : Clindamycin Phosphate,Adapalene,Benzoyl Peroxide

    Therapeutic Area : Dermatology

    Highest Development Status : Approved

    Sponsor : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    03

    Bausch Health

    Canada arrow
    Conjugates Summit
    Not Confirmed

    Bausch Health

    Canada arrow
    Conjugates Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Clindamycin Phosphate,Adapalene,Benzoyl Peroxide

    Therapeutic Area : Dermatology

    Study Phase : Approved

    Sponsor : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    FDA Approves Cabtreo(TM) (Clindamycin Phosphate, Adapalene and Benzoyl Peroxide) Topical Gel for the Treatment...

    Details : Cabtreo (Clindamycin Phosphate, Adapalene and Benzoyl Peroxide) Topical Gel which is indicated for the treatment of Acne Vulgaris in patients twelve years of age and older.

    Product Name : Cabtreo

    Product Type : Small molecule

    Upfront Cash : Not Applicable

    October 20, 2023

    Lead Product(s) : Clindamycin Phosphate,Adapalene,Benzoyl Peroxide

    Therapeutic Area : Dermatology

    Highest Development Status : Approved

    Sponsor : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    04

    Ortho Dermatologics

    U.S.A arrow
    Conjugates Summit
    Not Confirmed

    Ortho Dermatologics

    U.S.A arrow
    Conjugates Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Clindamycin Hydrochloride,Adapalene,Benzoyl Peroxide

    Therapeutic Area : Dermatology

    Study Phase : Phase III

    Sponsor : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Ortho Dermatologics Announces U.S. Food and Drug Administration New Drug Application Filing Acceptance for Inv...

    Details : IDP-126 (clindamycin 1.2%, adapalene 0.15%, benzoyl peroxide 3.1%) gel has the potential to be the first of its kind fixed dose triple combination treatment for acne vulgaris by inhibiting bacterial protein synthesis.

    Product Name : IDP-126

    Product Type : Small molecule

    Upfront Cash : Not Applicable

    May 01, 2023

    Lead Product(s) : Clindamycin Hydrochloride,Adapalene,Benzoyl Peroxide

    Therapeutic Area : Dermatology

    Highest Development Status : Phase III

    Sponsor : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    05

    Zydus Lifesciences

    India arrow
    Conjugates Summit
    Not Confirmed

    Zydus Lifesciences

    India arrow
    Conjugates Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Adapalene,Benzoyl Peroxide

    Therapeutic Area : Dermatology

    Study Phase : Approved

    Sponsor : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Ahmedabad-Based Zydus Gets USFDA Approval to Market Generic Acne Drug

    Details : A combination of Adapalene (a retinoid) and Benzoyl Peroxide (an antibiotic and skin-peeling agent), the gel is used to decrease the number and severity of acne pimples. The drug will be manufactured at the group's topical facility at Ahmedabad, Zydus Li...

    Product Name : Adapalene/Benzoyl Peroxide-Generic

    Product Type : Small molecule

    Upfront Cash : Not Applicable

    June 07, 2022

    Lead Product(s) : Adapalene,Benzoyl Peroxide

    Therapeutic Area : Dermatology

    Highest Development Status : Approved

    Sponsor : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    06

    Ortho Dermatologics

    U.S.A arrow
    Conjugates Summit
    Not Confirmed

    Ortho Dermatologics

    U.S.A arrow
    Conjugates Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Clindamycin Phosphate,Benzoyl Peroxide,Adapalene

    Therapeutic Area : Dermatology

    Study Phase : Phase III

    Sponsor : Bausch Health

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Ortho Dermatologics Will Present New Data at the 2022 American Academy of Dermatology Annual Meeting

    Details : IDP-126 Gel, an investigational drug, efficacy and safety of a fixed-dose clindamycin 1.2%, benzoyl peroxide 3.1%, and adapalene 0.15% gel for moderate-to-severe acne: randomized phase 2 and phase 3 studies of the first triple-combination drug.

    Product Name : IDP-126

    Product Type : Small molecule

    Upfront Cash : Not Applicable

    March 22, 2022

    Lead Product(s) : Clindamycin Phosphate,Benzoyl Peroxide,Adapalene

    Therapeutic Area : Dermatology

    Highest Development Status : Phase III

    Sponsor : Bausch Health

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    07

    Zydus Lifesciences

    India arrow
    Conjugates Summit
    Not Confirmed

    Zydus Lifesciences

    India arrow
    Conjugates Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Adapalene,Benzoyl Peroxide

    Therapeutic Area : Dermatology

    Study Phase : Approved

    Sponsor : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Zydus Cadila Receives Tentative Approval From USFDA for Adapalene and Benzoyl Peroxide Gel

    Details : Adapalene and Benzoyl Peroxide combination is used to treat acne. It works by killing the bacteria that cause acne and by keeping the skin pores clean.

    Product Name : Undisclosed

    Product Type : Small molecule

    Upfront Cash : Not Applicable

    October 08, 2021

    Lead Product(s) : Adapalene,Benzoyl Peroxide

    Therapeutic Area : Dermatology

    Highest Development Status : Approved

    Sponsor : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    08

    Perrigo Company plc

    Ireland arrow
    Conjugates Summit
    Not Confirmed

    Perrigo Company plc

    Ireland arrow
    Conjugates Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Adapalene

    Therapeutic Area : Dermatology

    Study Phase : Approved

    Sponsor : Altaris Capital Partners

    Deal Size : $1,550.0 million

    Deal Type : Divestment

    DEALS_DEV arrow-down

    Perrigo To Sell Generic Drugs Business for $1.55 Billion

    Details : Adapalene Cream indicated for the topical treatment of acne vulgaris in Perrigo Topical Generic Rx Business.

    Product Name : Undisclosed

    Product Type : Small molecule

    Upfront Cash : $1,500.0 million

    March 01, 2021

    Lead Product(s) : Adapalene

    Therapeutic Area : Dermatology

    Highest Development Status : Approved

    Sponsor : Altaris Capital Partners

    Deal Size : $1,550.0 million

    Deal Type : Divestment

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    09

    VYNE Therapeutics

    U.S.A arrow
    Conjugates Summit
    Not Confirmed

    VYNE Therapeutics

    U.S.A arrow
    Conjugates Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Minocycline Hydrochloride,Adapalene

    Therapeutic Area : Dermatology

    Study Phase : Phase II

    Sponsor : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    VYNE Therapeutics Reports Successful End-of-Phase 2 Meeting with the FDA for FCD105 in Acne

    Details : The meeting provided VYNE with clear direction on the Phase 3 clinical and pharmaceutical development plans for FCD105 and, should the clinical studies meet their objectives, the meeting provided further clarity on preparations required for the anticipat...

    Product Name : FCD105

    Product Type : Small molecule

    Upfront Cash : Not Applicable

    December 17, 2020

    Lead Product(s) : Minocycline Hydrochloride,Adapalene

    Therapeutic Area : Dermatology

    Highest Development Status : Phase II

    Sponsor : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    10

    Tarsier Pharma

    Israel arrow
    Conjugates Summit
    Not Confirmed

    Tarsier Pharma

    Israel arrow
    Conjugates Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : TRS01,Adapalene

    Therapeutic Area : Ophthalmology

    Study Phase : Phase II

    Sponsor : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Tarsier Pharma's Positive End-of-Phase 2 Meeting with the U.S. FDA Sets Stage for TRS01 Phase III Program in U...

    Details : Company received important feedback on its trial design and program for its TRS01 Phase 3 program in uveitis, including feedback on its nonclinical and CMC plans supporting submission of a New Drug Application (NDA) in the U.S.

    Product Name : TRS01

    Product Type : Undisclosed

    Upfront Cash : Not Applicable

    December 17, 2020

    Lead Product(s) : TRS01,Adapalene

    Therapeutic Area : Ophthalmology

    Highest Development Status : Phase II

    Sponsor : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth